ArticleThe AAPS journal2026
Single-Eye NfL Measurement Using NULISA Technology Enables Reduction in Animal Use.
Article in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurofilament light chain (NfL) is a pivotal biomarker for neuroaxonal damage. However, its quantification in volume-limited matrices, such as mouse aqueous humor (AH) (2 to 6 µL per eye), has historically required pooling samples from multiple animals due to the low sensitivity and high sample volume requirements of standard immunoassays. Such pooling increases animal requirements and precludes individual-level data analysis. To overcome these limitations, we developed and evaluated a NfL HomeBrew (HB) assay using the NUcleic acid-Linked Immuno-Sandwich Assay (NULISA) technology. NULISA offers superior analytical sensitivity and requires less than 10 µL volume. Our results demonstrate that the NfL HB NULISA performs comparably to the Simoa reference assay and provides superior sensitivity to the Ella platform. Crucially, the assay reliably quantified NfL in as little as 2 µL of individual mouse AH, with 90% of samples yielding quantifiable results. This approach eliminates the need for sample pooling, effectively reducing animal use by up to eightfold while preserving data integrity at the individual animal level. These findings establish the NULISA platform as a highly sensitive, ethically advantageous solution for neurobiological research in volume-restricted models.
Indexed as
Identifiers
41981365What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.